Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SV Clear all
Completed Not applicable Interventional

Trial With Deltex Cardio in Elective Bowel Resection Patients

NCT01244685
View directory record Official record
Conditions
1 Fluid Management
Interventions
Deltex CardioQ Probe
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 1 Interventional

Preoperative Radiation Therapy for High Risk Prostate Cancer

NCT01041326
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Radical Prostatectomy
Radiation · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence

NCT02202499
View directory record Official record
Conditions
Smoking Cessation, Tobacco Dependence
Interventions
Varenicline, Counseling and Support Materials, Laboratory Assessments
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 24, 2026, 4:09 PM EDT
Completed No phase listed Observational

Starling Registry Study

NCT04648293
View directory record Official record
Conditions
Hemodynamic Monitoring
Interventions
Starling
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Denver, Colorado • Quincy, Illinois • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 3 Interventional

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

NCT02145871
View directory record Official record
Conditions
Bladder Cancer
Interventions
standard fluid management, fluid management guided by the EV1000
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Micro and Macro Circulation in Sepsis

NCT05694455
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Starling Stroke Volume (Starling SV)- Passive Leg Raise, Microscan Sublingual Microscopy, Venous Excess Ultrasound Scoring (VExUS), Urine Collection
Diagnostic Test · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 99 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 24, 2026, 4:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Software Enhancements to the Respironics BiPAP autoSV Device Compared to BiPAP S/T Device

NCT01241604
View directory record Official record
Conditions
Sleep Disordered Breathing
Interventions
BiPAP S/T, BiPAP Auto SV3
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

NCT02831764
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

NCT03066947
View directory record Official record
Conditions
Breastcancer, Breast Neoplasm
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Santa Rosa, California • Plantation, Florida • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Fruquintinib, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Sonophoresis on Topical Anesthesia: A Pilot Study

NCT01283490
View directory record Official record
Conditions
Topical Anesthetic Applied With Sonophoresis
Interventions
DASD Group, Sonic Vibration (SV)
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Text Message Intervention for Alcohol Use and Sexual Violence in College Students

NCT05065918
View directory record Official record
Conditions
Alcohol Use, Unspecified, Sexual Violence, Sexual Assault
Interventions
sexual violence and alcohol use harm reduction text message content, alcohol use reduction content
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 24 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 24, 2026, 4:09 PM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03972605
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Non-Invasive Cardiac Output Monitor (NICOM) for Goal-directed Fluid Resuscitation for Inpatients With Hypotension and/or Septic Shock

NCT05630716
View directory record Official record
Conditions
Sepsis, Hypotension, Septic Shock
Interventions
NICOM
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 24, 2026, 4:09 PM EDT
Terminated Phase 3 Interventional

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

NCT02438007
View directory record Official record
Conditions
Prostate Cancer
Interventions
Galeterone, Enzalutamide
Drug
Lead sponsor
LTN PHARMACEUTICALS, INC.
Industry
Eligibility
18 Years and older · Male only
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
51
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings

NCT01755000
View directory record Official record
Conditions
Leukemia, Lymphoma, Paraproteinemias, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
USCOM scan, Fluid Bolus
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 24, 2026, 4:09 PM EDT
Not yet recruiting Phase 4 Interventional

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia

NCT06107335
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

NCT00621309
View directory record Official record
Conditions
Adverse Drug Interactions
Interventions
Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
Drug · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Expect Respect Middle School Randomized Trial

NCT04095429
View directory record Official record
Conditions
Adolescent Behavior, Violence in Adolescence, Group, Peer, Violence, Non-accidental, Violence, Sexual, Violence, Physical, Violence, Domestic, Emotional Abuse, Coping Skills, Communication, Personal
Interventions
Expect Respect, Enhanced Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
11 Years to 15 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 24, 2026, 4:09 PM EDT
Not listed Phase 3 Interventional

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

NCT00246727
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Selected Vegetable and Herb Mix
Drug
Lead sponsor
Sun Farm Corporation
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2011 · Synced Sep 24, 2026, 4:09 PM EDT
Completed No phase listed Observational Results available

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

NCT01894152
View directory record Official record
Conditions
Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease, Coronary Restenosis, Myocardial Infarction, Stent Thrombosis, Vascular Disease
Interventions
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Sep 24, 2026, 4:09 PM EDT
Recruiting Not applicable Interventional

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

NCT06271590
View directory record Official record
Conditions
Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Interventions
Sirolimus Drug Coated Balloon, Drug eluting stents (DES)
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
24
States / cities
Gilbert, Arizona • Los Angeles, California • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 24, 2026, 4:09 PM EDT
Withdrawn Phase 4 Interventional

Non-invasive Cardiac Output Monitoring in Obstetric Patients

NCT01516697
View directory record Official record
Conditions
Complications; Cesarean Section, Anesthesia; Adverse Effect, Spinal and Epidural
Interventions
experimental, Control
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 24, 2026, 4:09 PM EDT
Completed Phase 2 Interventional

Rifamycin in Minimal Hepatic Encephalopathy

NCT04082780
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
Rifamycin SV MMX, Placebo
Drug · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 24, 2026, 4:09 PM EDT